Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression
− AC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billion
− AC Immune to host conference call and webcast today at 8:30 a.m. ET
AC Immune management will host a conference call and webcast today at 8:30 a.m. ET to provide a brief overview of the agreement.
Monday, May 13 at 8:30 a.m. ET
Participants wishing to ask questions or to join the event via phone may call the following numbers 10 – 15 minutes before conference start:
United States | +1 (1) 631 570 56 13 |
Switzerland / Europe | +41 (0) 58 310 50 00 |
United Kingdom | +44 (0) 207 107 06 13 |
Other international numbers available |
Webcast:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=YteAZhdg
Please note that there is a function to type in your questions via webcast.
A live and archived webcast will also be accessible in the Investors section of the Company's website at https://www.acimmune.com/.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.